1. Academic Validation
  2. Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue

Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue

  • bioRxiv. 2023 Oct 12:2023.05.06.539698. doi: 10.1101/2023.05.06.539698.
Guoli Shi 1 Tiansheng Li 2 Kin Kui Lai 1 Reed F Johnson 2 Jonathan W Yewdell 2 Alex A Compton 1
Affiliations

Affiliations

  • 1 HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD.
  • 2 Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Abstract

Omicron emerged following COVID-19 vaccination campaigns, displaced previous SARS-CoV-2 variants of concern worldwide, and gave rise to lineages that continue to spread. Here, we show that Omicron exhibits increased infectivity in primary adult upper airway tissue relative to Delta. Using recombinant forms of SARS-CoV-2 and nasal epithelial cells cultured at the liquid-air interface, enhanced infectivity maps to the step of cellular entry and evolved recently through mutations unique to Omicron Spike. Unlike earlier variants of SARS-CoV-2, Omicron enters nasal cells independently of serine transmembrane proteases and instead relies upon metalloproteinases to catalyze membrane fusion. This entry pathway unlocked by Omicron Spike enables evasion of constitutive and interferon-induced Antiviral factors that restrict SARS-CoV-2 entry following attachment. Therefore, the increased transmissibility exhibited by Omicron in humans may be attributed not only to its evasion of vaccine-elicited adaptive immunity, but also to its superior invasion of nasal epithelia and resistance to the cell-intrinsic barriers present therein.

Figures
Products